India, Oct. 23 -- Eli Lilly and Company (India) Pvt. Ltd. and Cipla Ltd. have entered into a strategic agreement for the distribution and promotion of tirzepatide in India under the brand name Yurpeak®.
Under the pact, Cipla will distribute and promote Yurpeak®, expanding the availability of the diabetes and obesity treatment beyond cities where Lilly already operates. Lilly will continue manufacturing and supplying the drug at the same price as its existing brand, Mounjaro®.
Lilly India President and GM Winselow Tucker said the collaboration reinforces the company's commitment to expanding access to innovative treatments for chronic diseases such as type 2 diabetes and obesity.
Cipla's Global COO Achin Gupta said the partner...